Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan

Mutsumi Iwamoto, Satoshi Hirohata, Hiroko Ogawa, Takashi Ohtsuki, Ryouko Shinohata, Toru Miyoshi, Faruk O. Hatipoglu, Shozo Kusachi, Kazuhide Yamamoto, Yoshifumi Ninomiya

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Connective tissue growth factor (CTGF) is a secreted protein that regulates fibrosis. We hypothesized that CTGF is induced in a pressure-overloaded (PO) heart and that blocking the angiotensin II type 1 receptor would reduce CTGF expression. Accordingly, we administered olmesartan and compared its effects with other antihypertensive drugs in a PO heart. CTGF induction was determined in a rat PO model, and olmesartan, hydralazine or saline was continuously administered. The effects of olmesartan on CTGF induction, myocyte hypertrophy and fibrosis were evaluated. The effect of olmesartan on cardiac function was also examined in CTGF- and transforming growth factor-beta 1 (TGF-Β1)-infused rats. CTGF was increased in the PO heart 3 days after aortic banding and was markedly distributed around the perivascular fibrotic area. After 28 days, blood pressure was not significantly different in the olmesartan and hydralazine groups, but olmesartan treatment reduced CTGF distribution in PO hearts. Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4.77±0.48 for olmesartan and 6.05±1.45 for saline, P-1 for hydralazine, P

Original languageEnglish
Pages (from-to)1305-1311
Number of pages7
JournalHypertension Research
Volume33
Issue number12
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Connective Tissue Growth Factor
Angiotensin II Type 1 Receptor Blockers
Pressure
Hydralazine
Muscle Cells
Hypertrophy
Fibrosis
Angiotensin Type 1 Receptor
olmesartan
Antihypertensive Agents
Blood Pressure

Keywords

  • angiotensin receptor
  • fibrosis
  • growth factor
  • hypertrophy

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan. / Iwamoto, Mutsumi; Hirohata, Satoshi; Ogawa, Hiroko; Ohtsuki, Takashi; Shinohata, Ryouko; Miyoshi, Toru; Hatipoglu, Faruk O.; Kusachi, Shozo; Yamamoto, Kazuhide; Ninomiya, Yoshifumi.

In: Hypertension Research, Vol. 33, No. 12, 12.2010, p. 1305-1311.

Research output: Contribution to journalArticle

@article{8a21b923364f4584b074c993fa24294d,
title = "Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan",
abstract = "Connective tissue growth factor (CTGF) is a secreted protein that regulates fibrosis. We hypothesized that CTGF is induced in a pressure-overloaded (PO) heart and that blocking the angiotensin II type 1 receptor would reduce CTGF expression. Accordingly, we administered olmesartan and compared its effects with other antihypertensive drugs in a PO heart. CTGF induction was determined in a rat PO model, and olmesartan, hydralazine or saline was continuously administered. The effects of olmesartan on CTGF induction, myocyte hypertrophy and fibrosis were evaluated. The effect of olmesartan on cardiac function was also examined in CTGF- and transforming growth factor-beta 1 (TGF-Β1)-infused rats. CTGF was increased in the PO heart 3 days after aortic banding and was markedly distributed around the perivascular fibrotic area. After 28 days, blood pressure was not significantly different in the olmesartan and hydralazine groups, but olmesartan treatment reduced CTGF distribution in PO hearts. Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4.77±0.48 for olmesartan and 6.05±1.45 for saline, P-1 for hydralazine, P",
keywords = "angiotensin receptor, fibrosis, growth factor, hypertrophy",
author = "Mutsumi Iwamoto and Satoshi Hirohata and Hiroko Ogawa and Takashi Ohtsuki and Ryouko Shinohata and Toru Miyoshi and Hatipoglu, {Faruk O.} and Shozo Kusachi and Kazuhide Yamamoto and Yoshifumi Ninomiya",
year = "2010",
month = "12",
doi = "10.1038/hr.2010.189",
language = "English",
volume = "33",
pages = "1305--1311",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan

AU - Iwamoto, Mutsumi

AU - Hirohata, Satoshi

AU - Ogawa, Hiroko

AU - Ohtsuki, Takashi

AU - Shinohata, Ryouko

AU - Miyoshi, Toru

AU - Hatipoglu, Faruk O.

AU - Kusachi, Shozo

AU - Yamamoto, Kazuhide

AU - Ninomiya, Yoshifumi

PY - 2010/12

Y1 - 2010/12

N2 - Connective tissue growth factor (CTGF) is a secreted protein that regulates fibrosis. We hypothesized that CTGF is induced in a pressure-overloaded (PO) heart and that blocking the angiotensin II type 1 receptor would reduce CTGF expression. Accordingly, we administered olmesartan and compared its effects with other antihypertensive drugs in a PO heart. CTGF induction was determined in a rat PO model, and olmesartan, hydralazine or saline was continuously administered. The effects of olmesartan on CTGF induction, myocyte hypertrophy and fibrosis were evaluated. The effect of olmesartan on cardiac function was also examined in CTGF- and transforming growth factor-beta 1 (TGF-Β1)-infused rats. CTGF was increased in the PO heart 3 days after aortic banding and was markedly distributed around the perivascular fibrotic area. After 28 days, blood pressure was not significantly different in the olmesartan and hydralazine groups, but olmesartan treatment reduced CTGF distribution in PO hearts. Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4.77±0.48 for olmesartan and 6.05±1.45 for saline, P-1 for hydralazine, P

AB - Connective tissue growth factor (CTGF) is a secreted protein that regulates fibrosis. We hypothesized that CTGF is induced in a pressure-overloaded (PO) heart and that blocking the angiotensin II type 1 receptor would reduce CTGF expression. Accordingly, we administered olmesartan and compared its effects with other antihypertensive drugs in a PO heart. CTGF induction was determined in a rat PO model, and olmesartan, hydralazine or saline was continuously administered. The effects of olmesartan on CTGF induction, myocyte hypertrophy and fibrosis were evaluated. The effect of olmesartan on cardiac function was also examined in CTGF- and transforming growth factor-beta 1 (TGF-Β1)-infused rats. CTGF was increased in the PO heart 3 days after aortic banding and was markedly distributed around the perivascular fibrotic area. After 28 days, blood pressure was not significantly different in the olmesartan and hydralazine groups, but olmesartan treatment reduced CTGF distribution in PO hearts. Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4.77±0.48 for olmesartan and 6.05±1.45 for saline, P-1 for hydralazine, P

KW - angiotensin receptor

KW - fibrosis

KW - growth factor

KW - hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=78649813439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649813439&partnerID=8YFLogxK

U2 - 10.1038/hr.2010.189

DO - 10.1038/hr.2010.189

M3 - Article

VL - 33

SP - 1305

EP - 1311

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 12

ER -